The main shift in growth performance can be attributed to innovation. Both Elanco and Merck have invested in developing new product entrants targeting market segments that Zoetis has dominated, launching competitive products in the combination and long-acting parasiticide, and dermatology segments.
Another aspect of bolstering performance is product line balance. Elanco has the most balanced product line with a 51% companion animal (CA) /48% livestock (L) split into segments. Merck’s split is 40/60 and Zoetis is 67/32. Most industries, including animal health, run in cycles. Diversification is important to weather the ups and downs of the various market segments.
In the end, it looks like the industry will deliver overall growth rates in line with historical averages. To learn more about industry performance and trends, please join the Brakke team for the Annual Industry Overview presentation at both VMX in Orlando and WVC in Las Vegas in early 2027.
Senior Consultant
